Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fast-MRI could spot liver cancer earlier than ultrasound alone

NCT ID NCT05095714

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares adding a quick MRI scan (fast-MRI) to standard ultrasound every six months for detecting early-stage liver cancer in people with cirrhosis who are at high risk. About 944 participants will be randomly assigned to either ultrasound alone or ultrasound plus fast-MRI. The goal is to see if the combined approach finds more early cancers and is cost-effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Liver fast-MRI scan
What this could lead to
If successful, this could make fast-MRI the standard screening tool for early liver cancer in high-risk patients, catching more cancers at a curable stage.
What could go wrong
This is a Phase NA study, so results are not yet proven. Fast-MRI is more expensive and may not be cost-effective or widely available. The trial is still recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 944 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2022

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Patient enrolled in a screening program for at least 6 months in a tertiary hepatology center * Cirrhosis histologically proven or unequivocally suggested by non-invasive tests * Absence of HCC on imaging less than 3 months o * Liver parenchyma explorable by ultrasound * Child-Pugh A or B * Cirrhosis of non-viral or viral B/C cause controlled/healed * With an estimated annual risk of HCC\>3% * Written informed consent * Affiliation to a social security system Exclusion Criteria: * Child-Pugh C score * Active hepatitis B or C * Estimated annual risk of HCC\<3% * No prior enrollment in a screening program * Contraindication to Fast-MRI * Non-echogenic patient * Patient deprived of liberty * Patient under legal protection * Pregnant or breastfeeding woman * Patient on AME (state medical aid)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis liver cancer liver disorder Liver Neoplasms hepatocellular carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic liver disease Cirrhosis Hepatocellular carcinoma Liver cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assistance Publique Hôpitaux de Paris - Hôpital Avicenne

    RECRUITING

    Bondy, 93140, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.